the product in the database has an inactive status
indications:
Symptomatic treatment of bladder instability with impaired urination in patients with neurogenic bladder (urgency, urinary incontinence, difficulty urinating, overactivity of the detrusor).
Composition:
1 tabl powl. contains 5 mg of oxybutynin hydrochloride.
Action:
Anticholinergic drug. It has both direct spasmolytic activity on bladder smooth muscle and inhibits the action of acetylcholine on smooth muscle muscarinic receptors. In patients with involuntary bladder contraction, it increases the capacity of the bladder, reduces the frequency of spontaneous detrusor contractions and delays urinary urgency. After oral administration, it is rapidly absorbed from the gastrointestinal tract. The maximum concentration in the blood occurs within 0.5-1 h. Bioavailability is about 6%. Oxybutynin is metabolized in the liver and excreted in the urine. T0,5 in the blood is 2 hours.
Contraindications:
Hypersensitivity to the components of the preparation or other spasmolytic drugs. Glaucoma with closed angle of perception. Urination disorders associated with prostate hyperplasia (when there is a risk of urinary retention). Intestinal diseases (partial or total intestinal obstruction, paralytic ileus, intestinal atony in elderly patients, toxic widening of the large intestine, ulcerative colitis). Cardiovascular dysfunction following acute haemorrhage. Hyperthyroidism. Children under 5 years.
Precautions:
Use with caution in elderly patients, autonomic neuropathy, liver and kidney disease. Use during hot weather or in a very warm room can cause heat stroke (the preparation reduces perspiration). The product contains lactose - patients with hereditary galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption should not take the medicine.
Pregnancy and lactation:
Do not use during pregnancy, breast-feeding or women planning pregnancy.
Side effects:
The most common are: tachycardia, arrhythmia, agitation, dizziness, drowsiness, confusion, hallucinations, nightmares, convulsions, decreased libido, lactation, nausea, vomiting, diarrhea, constipation, dry mouth, discomfort in the cavity abdominal, lack of appetite, gastro-oesophageal reflux, urinary retention, difficulty in starting micturition, blurred vision, mydriasis, elevation of intraocular pressure, glaucoma with a closed angle of perception, paralysis of the eye muscles, dry eye syndrome, facial flushing (especially in children), dry skin, hypersensitivity reactions (rash, urticaria, angioneurotic edema, hypersensitivity to light). Oxybutynin may exacerbate the symptoms of hyperthyroidism, ischemic heart disease, congestive heart failure, hiatal hernia with gastroesophageal reflux, hypertension, benign prostatic hyperplasia and tachycardia.
Dosage:
Orally. Adults: usually 1 tabl. 2-3 times a day; the maximum daily dose is 20 mg; Elderly patients are initially given 1 tablet. 2 times a day, then the dose can be increased. Children over 5 years of age: 1 tabl. 2 times a day, then the dose can be increased to 1 tablet. 3 times per day; the maximum daily dose is 15 mg; in the case of bedwetting, the last dose should be administered at bedtime.
(C)
